CYP1B1 as a therapeutic target in cardio-oncology.
- Published in:
- Clinical Science, 2020, v. 134, n. 21, p. 2897, doi. 10.1042/CS20200310
- By:
- Publication type:
- Article
Works matching IS 01435221 AND DT 2020 AND VI 134 AND IP 21
Results: 9
1
2
Extracellular RNA in kidney disease: moving slowly but surely from bench to bedside.
- Published in:
- Clinical Science, 2020, v. 134, n. 21, p. 2893, doi. 10.1042/CS20201092
- By:
- Publication type:
- Article
3
The PAR-1 antagonist vorapaxar ameliorates kidney injury and tubulointerstitial fibrosis.
- Published in:
- Clinical Science, 2020, v. 134, n. 21, p. 2873, doi. 10.1042/CS20200923
- By:
- Publication type:
- Article
4
ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV.
- Published in:
- Clinical Science, 2020, v. 134, n. 21, p. 2851, doi. 10.1042/CS20200899
- By:
- Publication type:
- Article
5
Skeletal muscle redox signaling in rheumatoid arthritis.
- Published in:
- 2020
- By:
- Publication type:
- Literature Review
6
ACE2 and gut amino acid transport.
- Published in:
- Clinical Science, 2020, v. 134, n. 21, p. 2823, doi. 10.1042/CS20200477
- By:
- Publication type:
- Article
7
The molecular basis of immune-based platelet disorders.
- Published in:
- Clinical Science, 2020, v. 134, n. 21, p. 2807, doi. 10.1042/CS20191101
- By:
- Publication type:
- Article
8
ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery.
- Published in:
- 2020
- By:
- Publication type:
- Literature Review
9
Expression of Concern: Green tea polyphenols ameliorate metabolic abnormalities and insulin resistance by enhancing insulin signalling in skeletal muscle of Zucker Fatty Rats.
- Published in:
- Clinical Science, 2020, v. 134, n. 21, p. 2789, doi. 10.1042/CS-20200107_EOC
- Publication type:
- Article